June 25th 2025
Grace Therapeutics submits NDA for GTx-104, a promising IV treatment for aSAH, aiming to revolutionize patient care and improve outcomes.
Burst Expert Illustrations & Commentary™: Visualizing the Role of FcRN in Neurological Disorders
View More
BURST Expert Illustrations and Commentaries™: Visualizing FcRn as a Therapeutic Target in Neurological Disease
View More
BURST Expert Illustrations and Commentaries™: Visualizing the Implications of FcRN-Targeted Therapies on Generalized Myasthenia Gravis
View More
Clinical Consultations™: Navigating the Evolving Treatment Landscape in Generalized Myasthenia Gravis
View More
Burst Expert Illustrations & Commentary™: Visualizing the Role of Subcutaneous Infusion as an Alternate Administration Route for Medical Interventions
View More
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy
View More
Expert Illustrations & Commentaries™: New Targets for Treatment in Cognitive Impairment in Schizophrenia – The Role of NMDA Receptors and Co-agonists
View More
European Commission Approves Efgartigimod Subcutaneous Injection for Forms of CIDP
June 24th 2025Efgartigimod alfa SC is now approved in Europe for patients with chronic inflammatory demyelinating polyneuropathy, following a positive recommendation from the Committee for Medicinal Products for Human Use.
Exploring Cognitive Difficulties in Migraine: Aligning Subjective and Objective Findings
June 22nd 2025Laura Sebrow, PhD, a post doctoral neuropsychology fellow at North Shore University Hospital, discussed the relationship between patients’ reported cognitive difficulties and measurable cognitive performance during different migraine phases.
Targeting A3AR in Trigeminal Neuropathic Pain: A Promising Approach for an Unmet Clinical Need
June 21st 2025Marcela Romero-Reyes, DDS, PhD, FAHS, director of the Brotman Facial Pain Clinic at the University of Maryland, discussed a promising and potentially safer therapeutic approach for managing trigeminal neuropathic pain.
The Overlooked Role of Obstructive Sleep Apnea in Alzheimer Pathogenesis
Omonigho Michael Bubu, MD, PhD, an associate professor of psychiatry, neurology, & population health at NYU Langone, discussed how OSA contributes to Alzheimer disease risk through race- and sex-specific mechanisms and neurodegenerative biomarkers.
Overviewing SLEEP 2025: Thoughts and Perspectives From the President of AASM
Anita Shelgikar, MD, a clinical professor at the University of Michigan and president of the American Academy of Sleep Medicine, provided post-conference perspectives on the 2025 SLEEP meeting, giving clinicians insights on the latest in research and treatment updates.
Emerging Pharmacotherapies Offer New Hope in Obstructive Sleep Apnea Treatment
The director of sleep health at Flinders University discussed the latest clinical advances in pharmacotherapy, precision treatment targets, and combination strategies for obstructive sleep apnea.
Understanding Pediatric Insomnia: Risk Factors, Clinical Diagnosis, and Care Management
June 16th 2025Deepa Burman, MD, FAASM, co-director of the Pediatric Sleep Evaluation Center at UPMC Children’s Hospital of Pittsburgh, discussed the potential contributors to pediatric insomnia and the role of a thorough assessment for effective management.